Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 2;12:778978. doi: 10.3389/fimmu.2021.778978

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Cui, Jia, Xin, Zhang, Chen, Xia, Li, Xu, Chen, Feng, Wei, Yu, Wang, Zhan, Zhu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Pharmacodynamics and pharmacokinetic analysis in NCG mice. (A) HB0025 treatment compared with HB0023, HB002.1T, and HB0023+HB002.1T in NCG mice. (B) HB0025 treatment compared with bevacizumab, atezolizumab, and bevacizumab+atezolizumab in NCG mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared with HB0025_6mg/kg. (C) Tumor-infiltrating lymphocytes (CD3⁺, CD4⁺, CD8⁺) and the numbers of blood vessels (CD31⁺). *p < 0.05, **p < 0.01, ***p < 0.001 compared with the vehicle; ^#p < 0.05 compared HB0023 with HB0023+HB002.1T; ^$p < 0.05 compared HB002.1T with HB0023+HB002.1T; ^@p < 0.05 compared with HB0025 (3 mg/kg)/HB0025 (6 mg/kg) with HB0025 (12 mg/kg); and p < 0.05 compared HB002.1T+HB0023 with HB0025 (12 mg/kg). (D) The pharmacokinetic profiles of HB0025 in NCG mice at doses 3, 6, and 12 mg/kg. data expressed as mean ± SEM.